145 related articles for article (PubMed ID: 35137340)
1. Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.
Elbasha EH
Pharmacoeconomics; 2022 May; 40(5):497-507. PubMed ID: 35137340
[TBL] [Abstract][Full Text] [Related]
2. Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
Sendi P
Pharmacoeconomics; 2021 Feb; 39(2):161-169. PubMed ID: 33128734
[TBL] [Abstract][Full Text] [Related]
3. Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion.
Sendi P; Matter-Walstra K; Schwenkglenks M
Healthcare (Basel); 2021 Oct; 9(11):. PubMed ID: 34828466
[TBL] [Abstract][Full Text] [Related]
4. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
Elbasha EH
Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Portfolio Uncertainty in Decision Rules for Healthcare Resource Allocation.
Sendi P; Gafni A; Birch S; Walter SD
Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33799361
[TBL] [Abstract][Full Text] [Related]
6. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
7. How Uncertainty Matters Under Risk Neutrality.
Glynn D; Lomas J
Value Health; 2023 Aug; 26(8):1151-1154. PubMed ID: 37160252
[TBL] [Abstract][Full Text] [Related]
8. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
O'Brien BJ; Sculpher MJ
Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
[TBL] [Abstract][Full Text] [Related]
9. Risk preferences over health: Empirical estimates and implications for medical decision-making.
Mulligan K; Baid D; Doctor JN; Phelps CE; Lakdawalla DN
J Health Econ; 2024 Mar; 94():102857. PubMed ID: 38232447
[TBL] [Abstract][Full Text] [Related]
10. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
11. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
12. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
13. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
Guzauskas GF; Basu A; Carlson JJ; Veenstra DL
Value Health; 2019 Sep; 22(9):988-994. PubMed ID: 31511188
[TBL] [Abstract][Full Text] [Related]
14. Incorporating uncertainty and risk into decision making to reduce nitrogen inputs to impaired waters.
Martin DM; Johnson FA
J Environ Manage; 2019 Nov; 249():109380. PubMed ID: 31434050
[TBL] [Abstract][Full Text] [Related]
15. Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research.
Meltzer D
J Health Econ; 2001 Jan; 20(1):109-29. PubMed ID: 11148867
[TBL] [Abstract][Full Text] [Related]
16. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
Fenwick E; Marshall DA; Levy AR; Nichol G
BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
[TBL] [Abstract][Full Text] [Related]
17. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources.
Sendi P; Al MJ; Gafni A; Birch S
Soc Sci Med; 2003 Dec; 57(11):2207-15. PubMed ID: 14512250
[TBL] [Abstract][Full Text] [Related]
18. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
19. Effect of risk aversion on prioritizing conservation projects.
Tulloch AI; Maloney RF; Joseph LN; Bennett JR; Di Fonzo MM; Probert WJ; O'Connor SM; Densem JP; Possingham HP
Conserv Biol; 2015 Apr; 29(2):513-24. PubMed ID: 25327837
[TBL] [Abstract][Full Text] [Related]
20. Increasing the impact of budget impact analysis: incorporating uncertainty for decision-makers in small markets.
Hofmeister M; Clement F
Int J Technol Assess Health Care; 2022 Jan; 38(1):e15. PubMed ID: 35080195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
